182 related articles for article (PubMed ID: 35278170)
1. An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.
Mizukami T; Minashi K; Hara H; Nishina T; Amanuma Y; Takahashi N; Nakasya A; Takahashi M; Nakajima TE
Invest New Drugs; 2022 Jun; 40(3):614-621. PubMed ID: 35278170
[TBL] [Abstract][Full Text] [Related]
2. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K
Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Hayashi K; Furuta M; Furusawa K; Hamaguchi T; Watanabe M; Inokuchi Y; Onuma S; Hashimoto I; Suematsu H; Nagasawa S; Kanematsu K; Yamada T; Notsu A; Ogata T; Oshima T; Machida N; Furuse J; Maeda S
Anticancer Res; 2023 Jun; 43(6):2831-2840. PubMed ID: 37247885
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
Takahashi N; Hara H; Nagashima K; Hirata K; Masuishi T; Matsumoto T; Kawakami H; Yamazaki K; Hironaka S; Boku N; Muro K
BMC Cancer; 2023 Aug; 23(1):726. PubMed ID: 37543568
[TBL] [Abstract][Full Text] [Related]
5. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
[TBL] [Abstract][Full Text] [Related]
6. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
7. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
8. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J
ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.
Varghese AM; Cardin DB; Hersch J; Benson AB; Hochster HS; Makris L; Hamada K; Berlin JD; Saltz LB
Clin Cancer Res; 2020 Apr; 26(7):1555-1562. PubMed ID: 31924737
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Ilson DH; Tabernero J; Prokharau A; Arkenau HT; Ghidini M; Fujitani K; Van Cutsem E; Thuss-Patience P; Beretta GD; Mansoor W; Zhavrid E; Alsina M; George B; Catenacci D; McGuigan S; Makris L; Doi T; Shitara K
JAMA Oncol; 2020 Jan; 6(1):e193531. PubMed ID: 31600365
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Shitara K; Doi T; Hosaka H; Thuss-Patience P; Santoro A; Longo F; Ozyilkan O; Cicin I; Park D; Zaanan A; Pericay C; Özgüroğlu M; Alsina M; Makris L; Benhadji KA; Ilson DH
Gastric Cancer; 2022 May; 25(3):586-597. PubMed ID: 34997449
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
Doi T; Yoshino T; Fuse N; Boku N; Yamazaki K; Koizumi W; Shimada K; Takinishi Y; Ohtsu A
Invest New Drugs; 2015 Oct; 33(5):1068-77. PubMed ID: 26163340
[TBL] [Abstract][Full Text] [Related]
13. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Kehmann L; Berres ML; Gonzalez-Carmona M; Modest DP; Mohr R; Wree A; Venerito M; Strassburg C; Keitel V; Trautwein C; Luedde T; Roderburg C
BMC Cancer; 2023 May; 23(1):470. PubMed ID: 37217885
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma.
Dayyani F; Balangue J; Valerin J; Keating MJ; Zell JA; Taylor TH; Cho MT
Clin Colorectal Cancer; 2024 Mar; 23(1):67-72. PubMed ID: 38103947
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
Kato T; Kagawa Y; Kuboki Y; Gamoh M; Komatsu Y; Yasui H; Satake H; Oki E; Tanioka H; Kotaka M; Makiyama A; Denda T; Goto M; Yoshino T; Yamazaki K; Soeda J; Shibuya K; Iwata M; Oba K; Yamaguchi K
Int J Clin Oncol; 2021 Jul; 26(7):1238-1247. PubMed ID: 33928486
[TBL] [Abstract][Full Text] [Related]
16. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Saif MW; Becerra CR; Fakih MG; Sun W; Popovic L; Krishnamurthi S; George TJ; Rudek MA; Shepard DR; Skopek J; Sramek V; Zaric B; Yamamiya I; Benhadji KA; Hamada K; He Y; Rosen L
Cancer Chemother Pharmacol; 2021 Sep; 88(3):485-497. PubMed ID: 34097100
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Taniguchi H; Yamazaki K; Masuishi T; Kawakami T; Onozawa Y; Honda K; Kadowaki S; Narita Y; Tsushima T; Hamauchi S; Todaka A; Yokota T; Ando M; Mori K; Shirasu H; Yasui H; Muro K
Oncologist; 2023 Nov; 28(11):e1108-e1113. PubMed ID: 37284901
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T; Yamamoto Y; Kotaka M; Masuishi T; Tsuji Y; Shoji H; Hirata K; Tsuduki T; Makiyama A; Izawa N; Takahashi N; Tsuda M; Yasui H; Ohta T; Kito Y; Otsu S; Hironaka S; Yamazaki K; Boku N; Hyodo I; Yoshimura K; Muro K
Target Oncol; 2024 Mar; 19(2):181-190. PubMed ID: 38427280
[TBL] [Abstract][Full Text] [Related]
20. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Suenaga M; Wakatsuki T; Mashima T; Ogura M; Ichimura T; Shinozaki E; Nakayama I; Osumi H; Ota Y; Takahari D; Chin K; Seimiya H; Yamaguchi K
Invest New Drugs; 2020 Feb; 38(1):111-119. PubMed ID: 30838483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
